# Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer

> **NCT00039455** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- Male Breast Cancer
- Recurrent Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **DRUG:** alvocidib
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00039455
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-04
- **Primary completion:** 2004-12
- **Final completion:** —
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** Administratively complete.
- **Last updated:** 2013-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00039455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00039455, "Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00039455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*